Back to homepage

Cardiology and cardiovascular disease

Advances in safe insulin infusions

Authors: Fred Massoomi, Maureen Burger, Christine de Vries

This narrative review explores the expanding indications, risks and opportunities associated with insulin infusions and potential options for improved safety.

More▸

Ertugliflozin in the treatment of type 2 diabetes mellitus

Authors: Joel C Marrs PharmD, MPH, Sarah L Anderson PharmD

This narrative review aims to present and discuss the efficacy, safety, cardiovascular, and renal outcomes related to the use of ertugliflozin in Type 2 diabetes.

More▸

Role of renin–angiotensin–aldosterone system inhibitors in heart failure and chronic kidney disease

Authors: Namrata Singhania MD, Saurabh Bansal MD, Shreya Mohandas, Divya P Nimmatoori MD, Abutaleb A Ejaz MD, Girish Singhania MD

This narrative review summarizes the role of renin–angiotensin–aldosterone system inhibitors in acute and chronic heart failure and chronic kidney disease.

More▸

Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol

Authors: Teodoro Iturbe-Hernandez MD, Luis García de Guadiana Romualdo MD, Ignacio Gil Ortega MD, Antonio Martínez Francés MD, Olga Meca Birlanga MD, Juan José Cerezo-Manchado MD

In this review, the available information on the antithrombotic management of atrial fibrillation patients at discharge after COVID-19 infection is updated. In addition, a practical algorithm, considering renal and liver function, which facilitates the anticoagulation choice at discharge is presented.

More▸

Bempedoic acid for the treatment of dyslipidemia

Authors: Joel C Marrs PharmD, MPH, Sarah L Anderson PharmD

This narrative review aims to present and discuss the current evidence regarding the use of bempedoic acid for low-density lipoprotein-cholesterol lowering in patients with dyslipidemia and its potential role as an agent to lower cardiovascular events.

More▸